Distinguished in Endometrial Cancer

Dr. Mark E. Borowsky

Oncology
HMH - Obstetrics And Gynecology - Neptune
19 Davis Avenue, Floor 7, 
Neptune, NJ 
Distinguished in Endometrial Cancer
HMH - Obstetrics And Gynecology - Neptune
19 Davis Avenue, Floor 7, 
Neptune, NJ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Borowsky is an Oncologist in Neptune, New Jersey. Dr. Borowsky is rated as a Distinguished provider by MediFind in the treatment of Endometrial Cancer. His top areas of expertise are Endometrial Cancer, Endometrial Stromal Sarcoma, Malignant Mixed Mullerian Tumor, Ureteral Reconstruction, and Hernia Surgery.

His clinical research consists of co-authoring 17 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles and participated in 1 clinical trial in the study of Endometrial Cancer.

Graduate Institution
Perelman School Of Medicine At The University Of Pennsylvania
Residency
North Shore University Hospital-Manhasset
Specialties
Oncology
Licenses
Obstetrics & Gynecology in DE
Board Certifications
American Board Of Obstetrics And Gynecology
American Board Of Obstetrics And Gynecology
Fellowships
SUNY Downstate Medical Center
Hospital Affiliations
Ocean Medical Center
Riverview Medical Center
Jfk University Medical Center
Jersey Shore University Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Avalon Health Care
  • MEDICARE PDP
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

HMH - Obstetrics and Gynecology - Neptune
19 Davis Avenue, Floor 7, Neptune, NJ 7753.
Other Locations
1 Hospital Plaza, Suite 206, Old Bridge, NJ 8857.
HMH - Obstetrics and Gynecology - Forked River
730 Lacey Road, Suite 206, Forked River, NJ 8731.
HMH - Gynecologic Oncology - Jackson
27 South Cooks Bridge Road, Suite 2-19, Jackson, NJ 8527.

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cediranib Maleate, Durvalumab, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
Study Phase: Phase 2
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
Enrollment Status: Active_not_recruiting
Publish Date: December 10, 2024
Intervention Type: Other, Drug, Biological
Study Drugs: Bevacizumab, Carboplatin, Docetaxel, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Phase 2, Randomized, Open Label, Efficacy Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™ 2000 Alone or in Combination With Imiquimod, for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Vulva
A Phase 2, Randomized, Open Label, Efficacy Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™ 2000 Alone or in Combination With Imiquimod, for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Vulva
Enrollment Status: Completed
Publish Date: August 25, 2023
Intervention Type: Biological, Drug, Device
Study Drugs: VGX-3100, Imiquimod Cream
Study Phase: Phase 2
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
Enrollment Status: Unknown
Publish Date: March 29, 2023
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Enrollment Status: Completed
Publish Date: November 07, 2022
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Cisplatin, Paclitaxel
Study Phase: Phase 3
A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent With Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva (NCT #01595061)
A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent With Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva (NCT #01595061)
Enrollment Status: Unknown
Publish Date: December 29, 2021
Intervention Type: Drug, Procedure, Radiation
Study Drugs: Cisplatin, Gemcitabine Hydrochloride
Study Phase: Phase 2
View 6 Less Clinical Trials

17 Total Publications

Extended Venous Thromboembolism Prophylaxis after Robotic Staging for Endometrial Cancer.
Extended Venous Thromboembolism Prophylaxis after Robotic Staging for Endometrial Cancer.
Journal: Southern medical journal
Published: October 03, 2023
Similar Doctors
Carol A. Aghajanian
Elite in Endometrial Cancer
Dr. Carol A. Aghajanian
Oncology
Elite in Endometrial Cancer
Dr. Carol A. Aghajanian
Oncology

Memorial Developmental Chemo Group

1275 York Ave, 
New York, NY 
 (38.7 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Carol Aghajanian is an Oncologist in New York, New York. Dr. Aghajanian is rated as an Elite provider by MediFind in the treatment of Endometrial Cancer. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Ovarian Carcinosarcoma, and Salpingo-Oophorectomy.

Elite in Endometrial Cancer
Dr. Emily M. Ko
Oncology
Elite in Endometrial Cancer
Dr. Emily M. Ko
Oncology

Penn Gynecologic Oncology Washington Square

800 Walnut Street, 10th Floor, 
Philadelphia, PA 
 (61.6 miles away)
800-789-7366
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Emily Ko is an Oncologist in Philadelphia, Pennsylvania. Dr. Ko is rated as an Elite provider by MediFind in the treatment of Endometrial Cancer. Her top areas of expertise are Endometrial Cancer, Ovarian Cancer, Cervical Cancer, Lymphadenectomy, and Salpingo-Oophorectomy. Dr. Ko is currently accepting new patients.

Elite in Endometrial Cancer
Dr. Vicky Makker
Hematology Oncology | Oncology
Elite in Endometrial Cancer
Dr. Vicky Makker
Hematology Oncology | Oncology

Memorial Developmental Chemo Group

1275 York Ave, 
New York, NY 
 (38.7 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Vicky Makker is a Hematologist Oncology specialist and an Oncologist in New York, New York. Dr. Makker is rated as an Elite provider by MediFind in the treatment of Endometrial Cancer. Her top areas of expertise are Endometrial Cancer, Ovarian Cancer, Ovarian Carcinosarcoma, Lymphadenectomy, and Bone Graft.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Borowsky's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 11 Advanced Conditions
    View All 18 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile